NUCLEIX

Nucleix develops, manufactures, and markets non-invasive cancer tests designed to support earlier detection, when treatment may be most effective. Its products use the company’s EpiCheck platform technology, which aims to deliver highly accurate and sensitive results through a testing option designed to fit patients and healthcare systems.

The company’s Bladder EpiCheck test is CE-marked and available in Europe for primary and recurrent bladder cancer and upper urinary tract cancer. In the United States, it has FDA 510(k) clearance for monitoring recurrence of non-muscle invasive bladder cancer. Nucleix is also developing Lung EpiCheck, a blood test intended to detect early-stage lung cancer in high-risk individuals. Beyond these tests, the company says its research and development capabilities can support the creation of liquid biopsy assays for other cancer types.

Nucleix works with medical centers, healthcare organizations, and laboratories worldwide. Its stated mission is to advance cancer detection through non-invasive testing and international collaboration. The company has offices in Israel and the United States and provides information for patients, clinicians, and partners.